2-(2-methyloxazol-5-yl)acetic acid | 1276075-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-methyloxazol-5-yl)acetic acid
• 英文别名: 2-(2-Methyl-1,3-oxazol-5-yl)acetic acid
• CAS: 1276075-96-7
• 化学式: C₆H₇NO₃
• 分子量: 141.126
• InChiKey: JFQNTUTWWNJLBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-methyloxazol-5-yl)acetic acid 、 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以69%的产率得到N-[4-[2-[2-(2,2-difluoroethoxy)-5,6,8,9-tetrahydropyrido[2,3-d]azepin-7-yl]ethyl]-4-fluorocyclohexyl]-2-(2-methyl-1,3-oxazol-5-yl)acetamide
  参考文献：
  名称：

  EP3744721

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 2-(2-methyloxazol-5-yl)acetate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 以54.9 %的产率得到2-(2-methyloxazol-5-yl)acetic acid
  参考文献：
  名称：

  WO2023/147015

  摘要：

  公开号：

文献信息

• THERAPEUTIC PIPERAZINES
  申请人：Kaplan Alan P.

  公开号：US20110065691A1

  公开（公告）日：2011-03-17

  The invention includes a compound of formula I: wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.

  本发明涉及公式I的化合物：其中R1，Y，A，n，R4和Z具有本文所述的任何值，以及这些化合物的盐，包含这些化合物的组合物和治疗方法，包括给予这些化合物的管理。这些化合物是PDE4功能抑制剂，对于改善认知功能和/或治疗动物（特别是人类）的认知障碍或损伤、中枢和周围神经系统的创伤性和/或缺血性损伤和/或精神障碍非常有用。
• N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：Glick Gary D.

  公开号：US20140088094A1

  公开（公告）日：2014-03-27

  The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

  本发明提供四氢喹啉及相关化合物、制药组合物、抑制RORγ活性的方法、减少受试者体内IL-17的数量以及使用该四氢喹啉及相关化合物治疗免疫性疾病和炎症性疾病的方法。
• CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM
  申请人：Shionogi & Co., Ltd

  公开号：EP3744721A1

  公开（公告）日：2020-12-02

  Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)': wherein A is S or O; R1a is substituted or unsubstituted alkyloxy or the like, R2a to R2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R3 is each independently halogen or the like, r is an integer of 0 to 4, R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.

  提供了具有 D3 受体拮抗作用的新型化合物。 由式（IA）'代表的化合物： 其中 A 是 S 或 O；R1a 是取代或未取代的烷氧基或类似物；R2a 至 R2d 各自独立地是氢原子或类似物；环 B 是 4 至 8 元非芳族碳环或类似物；R3 各自独立地是卤素或类似物；r 是 0 至 4 的整数；R4 是取代或未取代的芳族杂环或类似物、 或其药学上可接受的盐。
• N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES
  申请人：Lycera Corporation

  公开号：EP2638014B1

  公开（公告）日：2017-01-04
• CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：US20210040117A1

  公开（公告）日：2021-02-11

  Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)′: wherein A is S or O; R 1a is substituted or unsubstituted alkyloxy or the like, R 2a to R 2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R 3 is each independently halogen or the like, r is an integer of 0 to 4, R 4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.